MECHANISM OF ANTIVIRAL ACTION AND EVALUATION OF THE EFFICACY OF THE NEW PREPARATION FORTEPREN® IN THE COMPLEX THERAPY OF CHRONIC RECURRENT HERPESVIRUS INFECTION OF GENITAL LOCALIZATION

Cover Page


Cite item

Abstract

Aim. The study of the mechanism of antiviral action and evaluation of the clinical efficacy, safety and tolerability of therapy with Fortepren® in patients with chronic recurrent herpesvirus infection of genital localization (CRHVI). Materials and methods. Clinical studies were carried out of a drug Fortepren® (0.4% sodium polyprenyl phosphate solution), which was administered to patients who underwent a basic therapeutic course of the drug Acyclovir-Acry® to relieve the acute phase of the disease. The study was performed on 80 male and female patients selected during the screening with a confirmed diagnosis of CRHVI. Two groups were formed. Patients of group 1 (experimental) were intramuscularly injected with Fortepren® at a dose of 2 ml (8 mg) three times at intervals of 21 days by 3 ± 2, 24 ± 2 and 45 ± 2 days following the 10-day basic course of treatment of the acute phase of diseases with the use of the acyclovir tablets of 400 mg - 13 ± 2, 34 ± 2 and 55 ± 2 days from the beginning of the study. Patients of the 2nd group (control) were intramuscularly injected with placebo solution at a volume of 2 ml instead of Fortepren®. To evaluate Fortepren® efficacy, the following criteria were used: increase in the duration of the inter-recessive period, a decrease in the frequency of relapses over the entire observation period; decrease in the severity of relapses, estimated in points, changes in immunological parameters according to the dynamics of changes in the production of the main cytokines. Results. In patients treated with Fortepren®, the inter-recurrence period for the entire study period increased statistically from 29.36 ± 2.16 to 42.98 ± 3.29 days, while in the control group this indicator have not changed. Accordingly, in patients treated with Fortepren®, a statistically significant reduction in the incidence of recurrence of CRHVI from 3.03 ± 0.02 before treatment to 1.94 ± 0.19 was observed during treatment in the absence of a decrease in the frequency of relapses in the control. Evaluation of the severity of CRHVI relapses in patients treated with Fortepren® indicates the efficacy of this protocol. The sum of the scores of the mean values of CRHVI symptoms signs was statistically significantly decreased in the group 1 from 7.36 ± 0.35 points at the 1 st visit before the start of treatment to 4.75 ± 0.35 points during the treatment. No changes were seen in the control group. The level of leukocyte virus-induced interferon (LVI-IFN) in the patients of the group 1 increased from 36% to 64% in the end of the clinical trial compared to the control group, in which the increase in LVI-IFN titers was not observed. To further justify the possibility of increasing the immune response of cells, establishing possible mechanisms that determine the efficacy of treatment for CRHVI with Fortepren®, evaluation of the production of IFNz, IFNy, IL-10, IL-12p40, IL-12p70, IL-15, IL-2, IL-4, MIF-Fz, TNFа was made. In the of the study levels of all these cytokines was increased in patients treated with Fortepren® compared with the control group. Conclusion. The efficacy of using Fortepren® in a dose of 2 ml (8 mg) with intramuscular administration to patients with chronic recurrent herpesviral infection of genital localization at the stage of remission three times with an interval of 21 days by 3 ± 2, 24 ± 2 and 45 ± 2 days after the end of 10 day basic course of treatment of the acute phase of the disease with the use of the drug acyclovir.

About the authors

A. M. Sedov

Gamaleya National Research Centre of Epidemiology and Microbiology

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

A. N. Narovlyansky

Gamaleya National Research Centre of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

A. V. Pronin

Gamaleya National Research Centre of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

A. V. Sanin

Gamaleya National Research Centre of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

I. K. Zubashev

Gamaleya National Research Centre of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

A. V. Izmestieva

Gamaleya National Research Centre of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

A. M. Ivanova

Gamaleya National Research Centre of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

T. M. Parfenova

Gamaleya National Research Centre of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

A. E. Shulzhenko

State Scientific Centre Institute of Immunology

Email: noemail@neicon.ru
Russian Federation

I. N. Zuikova

State Scientific Centre Institute of Immunology

Email: noemail@neicon.ru
Russian Federation

R. V. Shubelko

State Scientific Centre Institute of Immunology

Email: noemail@neicon.ru
Russian Federation

A. A. Khaldin

Moscow Scientific and Practical Centre of Dermatovenerology and Cosmetology

Email: noemail@neicon.ru
Russian Federation

D. R. Isaeva

Moscow Scientific and Practical Centre of Dermatovenerology and Cosmetology

Email: noemail@neicon.ru
Russian Federation

E. P. Selkova

Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

E. A. Grigorieva

Gamaleya National Research Centre of Epidemiology and Microbiology

Email: noemail@neicon.ru
Russian Federation

References

  1. Васильев А.Н., Ожерелков С.В., Козлов В.В. Противовирусная и иммуномодулирующая активность полипренилфосфатов при вирусных инфекциях. Антибиотики и химеотерапия. 2008, 53 (3-4): 3-8.
  2. ВОЗ. Вирус простого герпеса. Информационный бюллетень. Январь 2017 г. http:// www.who.int/mediacentre/factsheets/fs400/ru/.
  3. Кузнецова И.В., Хлыстова Е.А. Генитальный герпес: современные подходы к решению проблемы (обзор литературы). Эффективная фармакотерапия. Дерматовенерология и дерматокосметология. Спецвыпуск. 2016, 1: 30.
  4. Наровлянский А.Н., Седов А.М., Пронин А.В. Лечение больных с хронической рецидивирующей герпесвирусной инфекцией генитальной локализации: клиническое исследование препарата Фортепрен®. Журн. микробиол. 2015, 4: 112-118.
  5. Семенова Т.Б. Принципы лечения простого герпеса. РМЖ, 2002 (20): 924-930.
  6. Халдин А.А., Игнатьев Д.В. Новый индуктор интерферона Кагоцел в терапии простого герпеса: возможности и перспективы. Эффективная фармакотерапия. Дерматология и венерология.2011, 2: 14-18.
  7. Шульженко А.Е. Герпетические инфекции человека. Перспективы диагностики и противовирусной терапии. СПб, Цитокины и воспаление. 2005, 4 (3): 76-81.
  8. Шульженко А.Е., Зуйкова И.Н. Подходы к иммунотерапии рецидивирующего простого герпеса. Эффективная фармакотерапия в акушерстве и гинекологии. 2010, 3: 10-15.
  9. Pronin A.V., Narovlyansky A.N., Shulzhenko A.E., Sanin A.V., Sedov A.M. New polyprenyl phosphate based preparation Fortepren® as promising cytokine regulationg antiviral remedy. Cytokine and Growth Factor Reviews. 2016, 30: 119-126.

Copyright (c) 2018 Sedov A.M., Narovlyansky A.N., Pronin A.V., Sanin A.V., Zubashev I.K., Izmestieva A.V., Ivanova A.M., Parfenova T.M., Shulzhenko A.E., Zuikova I.N., Shubelko R.V., Khaldin A.A., Isaeva D.R., Selkova E.P., Grigorieva E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies